Should I buy or sell IN8bio stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INAB shares. View INAB analyst ratings or view top-rated stocks .

What is IN8bio's stock price target for 2024?

2 Wall Street analysts have issued 1 year price targets for IN8bio's stock. Their INAB share price targets range from $7.50 to $14.00. On average, they anticipate the company's share price to reach $10.75 in the next twelve months. This suggests a possible upside of 923.8% from the stock's current price. View analysts price targets for INAB or view top-rated stocks among Wall Street analysts .

How have INAB shares performed in 2024?

IN8bio's stock was trading at $1.38 on January 1st, 2024. Since then, INAB shares have decreased by 23.9% and is now trading at $1.05. View the best growth stocks for 2024 here .

Are investors shorting IN8bio?

IN8bio saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 51,600 shares, a decrease of 39.2% from the March 15th total of 84,800 shares. Based on an average daily volume of 168,200 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company's shares are sold short. View IN8bio's Short Interest .

When is IN8bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our INAB earnings forecast .

How were IN8bio's earnings last quarter?

IN8bio, Inc. (NASDAQ:INAB) announced its quarterly earnings results on Thursday, March, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.05.

IN8bio (INAB) raised $44 million in an IPO on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities served as the underwriter for the IPO.

How do I buy shares of IN8bio?

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:INAB

IN8bio (INAB) Stock Price, News & Analysis

→ 3 Sub-$10 Stocks to Buy for 2024 (From TradingTips) (Ad)

Free INAB Stock Alerts

$1.05

+0.05 (+5.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.99
▼
$1.05
50-Day Range: $0.95
▼
$1.30
52-Week Range: $0.65
▼
$3.95

Volume: 125,408 shs
Average Volume: 712,654 shs
Market Capitalization: $33.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.75

Get IN8bio alerts:

IN8bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 923.8% Upside
$10.75 Price Target
Short Interest: Healthy
0.18% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.70) to ($0.42) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.01 out of 5 stars

Medical Sector

382nd out of 918 stocks

Biological Products, Except Diagnostic Industry

56th out of 154 stocks

3.5

Analyst's Opinion

Consensus Rating
IN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
IN8bio has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.18% of the float of IN8bio has been sold short.
Short Interest Ratio / Days to Cover
IN8bio has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in IN8bio has recently decreased by 39.15%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
IN8bio does not currently pay a dividend.
Dividend Growth
IN8bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INAB.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for IN8bio this week, compared to 1 article on an average week.
Search Interest
8 people have searched for INAB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
2 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IN8bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
33.00% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for IN8bio are expected to grow in the coming year, from ($0.70) to ($0.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IN8bio is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IN8bio is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IN8bio has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)

[Get Your Insights Now]

About IN8bio Stock (NASDAQ:INAB)

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

INAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INAB Stock News Headlines

April 16, 2024 | globenewswire.com

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

April 12, 2024 | markets.businessinsider.com

Promising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR Platform

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 11, 2024 | americanbankingnews.com

IN8bio's (INAB) "Buy" Rating Reiterated at HC Wainwright

April 10, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: TRACON Pharmaceuticals (TCON) and IN8bio (INAB)

April 10, 2024 | msn.com

Kill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows Potential

April 9, 2024 | globenewswire.com

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

March 28, 2024 | finance.yahoo.com

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

March 20, 2024 | investing.com

Laidlaw sets INAB stock to buy, targets $7.50 price

March 14, 2024 | investorplace.com

INAB Stock Earnings: IN8bio Misses EPS for Q4 2023

March 14, 2024 | globenewswire.com

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

March 13, 2024 | markets.businessinsider.com

Buy Recommendation Based on IN8bio’s Promising γ δ T Cell Therapy Developments and Positive Clinical Trial Outcomes

March 5, 2024 | globenewswire.com

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

February 26, 2024 | businesswire.com

IN8bio to Present at Upcoming Investor Conferences

February 14, 2024 | finanznachrichten.de

IN8bio, Inc: IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

February 14, 2024 | finance.yahoo.com

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

February 14, 2024 | globenewswire.com

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

February 13, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), CymaBay Therapeutics (CBAY)

January 4, 2024 | msn.com

In8bio stock jumps 11% following clinical update

January 4, 2024 | finance.yahoo.com

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

December 18, 2023 | ca.finance.yahoo.com

IN8bio, Inc. (INAB) Stock Price, News, Quote & History - Yahoo Finance

December 14, 2023 | markets.businessinsider.com

Buy Rating for IN8bio Amidst Promising Leukemia Treatment Advances and Robust Clinical Data

December 11, 2023 | finance.yahoo.com

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

December 7, 2023 | finanznachrichten.de

IN8bio, Inc: IN8bio Appoints Dr. Corinne Epperly to Board of Directors

December 7, 2023 | finance.yahoo.com

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

December 5, 2023 | finance.yahoo.com

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

See More Headlines

Receive INAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:INAB
CUSIP: N/A
CIK: 1740279
Web: www.in8bio.com
Phone: 646-600-6438
Fax: N/A
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.75
High Stock Price Target: $14.00
Low Stock Price Target: $7.50
Potential Upside/Downside: +923.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,010,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -147.67%
Return on Assets: -105.00%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 4.57
Quick Ratio: 4.57

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.78 per share
Price / Book: 1.35

Miscellaneous

Outstanding Shares: 31,990,000
Free Float: 21,434,000
Market Cap: $33.59 million
Optionable: Not Optionable
Beta: -0.01

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Tai-Wei Ho (Age 47)
Co-Founder, President, CEO & Director
Comp: $837k
Dr. Kate Rochlin Ph.D. (Age 43)
Chief Operating Officer
Comp: $565.4k
Dr. Trishna Goswami M.D. (Age 46)
Chief Medical Officer
Comp: $638.51k
Dr. Lawrence S. Lamb Ph.D. (Age 70)
Executive VP, Co-Founder & Chief Scientific Officer
Comp: $482.47k
Mr. Patrick McCall CPA (Age 41)
CFO & Secretary
Comp: $519.35k
Mr. Michael McNamara
Vice President of Accounting

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INAB Stock Analysis - Frequently Asked Questions

Should I buy or sell IN8bio stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INAB shares.
View INAB analyst ratings or view top-rated stocks.
What is IN8bio's stock price target for 2024?: 2 Wall Street analysts have issued 1 year price targets for IN8bio's stock. Their INAB share price targets range from $7.50 to $14.00. On average, they anticipate the company's share price to reach $10.75 in the next twelve months. This suggests a possible upside of 923.8% from the stock's current price.
View analysts price targets for INAB or view top-rated stocks among Wall Street analysts.
How have INAB shares performed in 2024?: IN8bio's stock was trading at $1.38 on January 1st, 2024. Since then, INAB shares have decreased by 23.9% and is now trading at $1.05.
View the best growth stocks for 2024 here.
Are investors shorting IN8bio?: IN8bio saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 51,600 shares, a decrease of 39.2% from the March 15th total of 84,800 shares. Based on an average daily volume of 168,200 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company's shares are sold short.
View IN8bio's Short Interest.

When is IN8bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our INAB earnings forecast.
How were IN8bio's earnings last quarter?: IN8bio, Inc. (NASDAQ:INAB) announced its quarterly earnings results on Thursday, March, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.05.
When did IN8bio IPO?: IN8bio (INAB) raised $44 million in an IPO on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities served as the underwriter for the IPO.
How do I buy shares of IN8bio?: Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INAB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial